Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
11.792 / 17.032
#94329

Re: Farmas USA

NVIV

Invivo Therapeutics (NVIV) to Make Late-Breaking Presentation on INSPIRE Trial at Congress of Neurological Surgeons

titled “Clinical-Pathological Assessment of Severe (AIS A) Traumatic Acute Thoracic Spinal Cord Injury: Post-Durotomy/Myelotomy Observations from the INSPIRE Trial” at the 2016 Congress of Neurological Surgeons (CNS) Annual Meeting on September 28, 2016. The abstract was one of the top three late-breaking abstracts chosen for an oral presentation.

“INSPIRE has provided new insights into acute spinal cord injury pathology, allowing for the application of the Neuro-Spinal ScaffoldTM as a potential new treatment modality for complete spinal cord injury. I’m looking forward to sharing the findings with the neurosurgical community,” Dr. Fehlings said.

http://www.streetinsider.com/Corporate+News/Invivo+Therapeutics+%28NVIV%29+to+Make+Late-Breaking+Presentation+on+INSPIRE+Trial+at+Congress+of+Neurological+Surgeons/12052971.html?si_client=intbro

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#94330

Re: Farmas USA

NVIV

Pues igual le puedes meter corto hasta ese día. Lleva ya unas cuantas sesiones jugueteando con la alcista y cualquier día que venga el IBB en modo sangre se la zampa!

#94331

Re: Farmas USA

AERI

Initiated by HC Wainwright at buy. $66.00 PT y un par de PO más en el rango de los 50-55.

En la oferta de venta de acciones, página 20:

Stabilization . In connection with this offering, the underwriter may engage in stabilizing transactions, overallotment transactions, syndicate covering transactions and purchases to cover positions created by short sales in accordance with Regulation M under the Exchange Act.


• Stabilizing transactions permit bids to purchase shares of common stock so long as the stabilizing bids do not exceed a specified maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the common stock while the offering is in progress.


• Overallotment transactions involve sales by the underwriter of shares of common stock in excess of the number of shares of common stock the underwriter is obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of shares of common stock overallotted by the underwriter, if any, is not greater than the number of shares of common stock that they may purchase in the option to purchase additional shares. In a naked short position, the number of shares of common stock involved is greater than the number of shares of common stock in the option to purchase additional shares, if any. The underwriter may close out any short position by exercising their option to purchase additional shares, if any, and/or purchasing shares of common stock in the open market.


Syndicate covering transactions involve purchases of common stock in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source

of shares of common stock to close out the short position, the underwriter will consider, among other things, the price of shares of common stock available for purchase in the open market as compared with the price at which the underwriter may purchase shares of common stock through exercise of the option to purchase additional shares, if any. If the underwriter sells more shares of common stock than could be covered by exercise of the option to purchase additional shares, if any, and, therefore, has a naked short position, the position can be closed out only by buying shares of common stock in the open market. A naked short position is more likely to be created if the underwriter is concerned that after pricing there could be downward pressure on the price of the shares of common stock in the open market that could adversely affect investors who purchase in the offering.

These stabilizing transactions and syndicate covering transactions may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the underwriter make any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may be effected on The Nasdaq Global Market, in the over-the-counter market or otherwise and, if commenced, may be discontinued at any time.

http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11598240&RcvdDate=9/19/2016&CoName=AERIE%20PHARMACEUTICALS%20INC&FormType=424B5&View=html

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#94332

Re: Farmas USA

NVIV

Es posible. He calculado que habría que meterle largo a mediados de noviembre. En diciembre darán actualización de estado a 6 meses de uno de los enfermos que faltan.

Editado: sí, meterle largo en este caso, Mugi.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#94333

Re: Farmas USA

TBRA
Buah. La tenía la primera en la lista, esperando cerca de $4.3.

La añadí a la lista al leer a whitecoatmafia, puso que era una jugada parecida a RLYP. Acertó, pero debe estar contento porque creo que vendió casi todas hace muy poco...

#94334

Re: Farmas USA

NVIV

"Hay que meterle"... largo, no? Que ya me confundes... Yo sigo esperando los 5,3x-4x a ver si se dan durante octubre y esperar los ER de Q3 des de fuera

#94335

Re: Farmas USA

GALE:

Gracias de nuevo. Me he podido salir bastante bien para como estaba el tema

Si te sientas en la mesa y no descubres al "primo" es que lo eres tú.

#94336

Re: Farmas USA

TBRA Yo la compré este verano cuando la comenté por aquí. hay mucho interés en NASH por las Farmas aunque me inclinaba más en un BO por GILD y el premium me ha sorprendido.

Te puede interesar...
  1. Primeras dudas sobre la 'Trumponomics', ¿corrección o toma de beneficios?